Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acasunlimab + docetaxel
- Development stage
- Discontinued
- Lead developer
- Genmab
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Acasunlimab + docetaxel is an investigational combination therapy being studied primarily for the treatment of PD-L1-positive metastatic non-small cell lung cancer (NSCLC). Acasunlimab (also known as GEN1046 or DuoBody-PD-L1×4-1BB) is a bispecific monoclonal antibody that targets both PD-L1 and 4-1BB to enhance immune-mediated anti-tumor activity. Docetaxel is a well-established chemotherapeutic agent in the taxane class that inhibits microtubule depolymerization, thereby disrupting cell division and inducing apoptosis in cancer cells. The combination aims to leverage immune activation with cytotoxic chemotherapy for improved efficacy in patients who have progressed after prior immunotherapy and platinum-based chemotherapy[1][2][3][6].
02
Targets
TNFRSF9 (CD137 extracellular domain)CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on acasunlimab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acasunlimab + docetaxel.